Zobrazeno 1 - 10
of 64
pro vyhledávání: '"SB-206553"'
Publikováno v:
Frontiers in Neural Circuits
Frontiers in Neural Circuits, Vol 14 (2020)
Frontiers in Neural Circuits, Vol 14 (2020)
Applying serotonergic (5-HT) agonists or grafting of fetal serotonergic cells into the spinal cord improves locomotion after spinal cord injury. Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administer
Publikováno v:
Progress In Neurobiology
Artículos CONICYT
CONICYT Chile
instacron:CONICYT
Artículos CONICYT
CONICYT Chile
instacron:CONICYT
Evidence so far indicates that therapies targeting a single aspect of Alzheimer's disease (AD) have no sufficient efficacy in diminishing long-term the progression of AD. Neuroinflammation is an early event during the development of the disease and i
Publikováno v:
Journal of Behavioral and Brain Science. :454-462
Deficits in serotonin (5-hydroxytryptamine, 5-HT) neurotransmission are implicated in abnormal emotional behaviors such as aggression, anxiety, and depression. However, the specific 5-HT receptor mechanisms involved are not well understood. The role
Autor:
Miyuki Yokota, Akiyoshi Urano, Tsutomu Oshima, Yuhji Saitoh, Hirokazu Nagatani, Yoshinori Nakata
Publikováno v:
Journal of Anesthesia. 25:225-228
Blockade of 5-hydroxytryptamine (5-HT)(2A) receptors reportedly mediates or modulates the ability of isoflurane to produce immobility during noxious stimulation and would thereby influence MAC (the minimum alveolar concentration required to suppress
Publikováno v:
Pharmacological Reports. 63:45-53
The aim of this study was to analyze functional properties of the naturally occurring C23S variant of the human 5-HT 2C receptor. In HEK293 cells transiently expressing the unedited forms of the variant receptor (VR) or the wild-type receptor (WTR),
5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson’s disease
Publikováno v:
Neuropharmacology. 59:31-36
Clinical observations have suggested that ritanserin, a 5-HT(2A/C) receptor antagonist may reduce motor deficits in persons with Parkinson's Disease (PD). To better understand the potential antiparkinsonian actions of ritanserin, we compared the effe
Autor:
Michel Bourin, Martine Hascoët
Publikováno v:
Behavioural Brain Research. 208:352-358
Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepine and neurosteroids but potentiating GABA A receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of b
Autor:
Fabrizio Sitzia, Renza Roncarati, Thomas A. Comery, Brian Jow, Mark R. Bowlby, Dianne Kowal, Flora Jow, Adam M. Gilbert, Veronica Soloveva, Larocque James Paul, Tim Lock, Angela Kramer, John Dunlop, Andrew D. Randall, Steven M. Grauer, Jon T. Brown
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 328:766-776
The α7 nicotinic acetylcholine receptor (nAChR) has been implicated in Alzheimer's disease and schizophrenia, leading to efforts targeted toward discovering agonists and positive allosteric modulators (PAMs) of this receptor. In a Ca2+ flux fluorome
Autor:
Jessica E. Malberg, Gary Paul Stack, James E. Barrett, Sharon Rosenzweig-Lipson, John Dunlop, Annmarie Louise Sabb, Steven M. Grauer, P J Mitchell, Stacey J. Sukoff Rizzo, Julie A. Brennan, John F. Cryan, Karen L. Marquis, Irwin Lucki
Publikováno v:
Psychopharmacology. 192:159-170
Activation of one or more of the serotonin (5-HT) receptors may play a role in mediating the antidepressant effects of SSRIs. The present studies were conducted to evaluate the effects of the novel 5-HT2C receptor agonist WAY-163909 in animal models
Autor:
Jans Alzate-Morales, Miguel Reyes-Parada, Gabriel Núñez-Vivanco, J. Sebastián Contreras-Riquelme, Patricio Iturriaga-Vásquez, Hugo R. Arias, Patricia Moller-Acuna, Cecilia Rojas-Fuentes
Publikováno v:
Plos One
Artículos CONICYT
CONICYT Chile
instacron:CONICYT
PLoS ONE, Vol 10, Iss 8, p e0134444 (2015)
PLoS ONE
Artículos CONICYT
CONICYT Chile
instacron:CONICYT
PLoS ONE, Vol 10, Iss 8, p e0134444 (2015)
PLoS ONE
Evidence from systems biology indicates that promiscuous drugs, i.e. those that act simultaneously at various protein targets, are clinically better in terms of efficacy, than those that act in a more selective fashion. This has generated a new trend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7938ce454e0e28c7c6a15210dc153f51